In summary, the absence of TB reactivation in secukinumab clinical studies17 (and further detailed here) is moreover supported by experimental in vitro studies showing lack of effect of secukinumab on M. tuberculosis dormancy in a human in vitro microgranuloma model (this study), and lack of compromised host resistance in anti-IL-17A-treated M. tuberculosis-infected mice.37 Collecting real-world evidence data, through registries, will be an opportunity to further substantiate the safety of secukinumab in this regard. Here, IL17A is linked to tuberculosis.